Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Benner

Showing results (311-320 of 347) with videos related to

Pageof 35
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2023
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple MyelomaLisa B Leypoldt, Diana Tichy, Britta Besemer, et al.
Gastroenterology|November 7, 2007
DMBT1 confers mucosal protection in vivo and a deletion variant is associated with Crohn's diseaseMarcus Renner, Gaby Bergmann, Inge Krebs, et al.
Breast Cancer Research and Treatment|October 1, 2011
CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancerFrederik Marmé, Wiebke Werft, Anne Walter, et al.
Future Oncology (London, England)|September 30, 2024
Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myelomaLisa B Leypoldt, Diana Tichy, Britta Besemer, et al.
European Urology Oncology|June 1, 2026
MRI Quality and Reader Experience in Organized Prostate Cancer Screening: Insights from the PROBASE TrialMatthias Boschheidgen, Rouvier Al-Monajjed, Heinz-Peter Schlemmer, et al.
European Urology Oncology|November 11, 2025
Value of Additional Systematic Cores During Magnetic Resonance Imaging-guided Targeted Biopsy in Prostate Cancer Screening for Young Men: Results from the PROBASE TrialRouvier Al-Monajjed, Matthias Boschheidgen, Jale Lakes, et al.
Acta Neuropathologica|March 23, 2011
Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytomaHuriye Cin, Claus Meyer, Ricarda Herr, et al.
Blood Advances|September 30, 2024
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurinFrank G Rücker, Lars Bullinger, Sibylle Cocciardi, et al.
Nature Communications|September 22, 2020
The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolutionAlexej Ballhausen, Moritz Jakob Przybilla, Michael Jendrusch, et al.
Blood Advances|April 29, 2022
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplicationsHartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
Pageof 35

Showing results (311-320 of 347) with videos related to

Sort By:
Pageof 35
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2023
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple MyelomaLisa B Leypoldt, Diana Tichy, Britta Besemer, et al.
Gastroenterology|November 7, 2007
DMBT1 confers mucosal protection in vivo and a deletion variant is associated with Crohn's diseaseMarcus Renner, Gaby Bergmann, Inge Krebs, et al.
Breast Cancer Research and Treatment|October 1, 2011
CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancerFrederik Marmé, Wiebke Werft, Anne Walter, et al.
Future Oncology (London, England)|September 30, 2024
Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myelomaLisa B Leypoldt, Diana Tichy, Britta Besemer, et al.
European Urology Oncology|June 1, 2026
MRI Quality and Reader Experience in Organized Prostate Cancer Screening: Insights from the PROBASE TrialMatthias Boschheidgen, Rouvier Al-Monajjed, Heinz-Peter Schlemmer, et al.
European Urology Oncology|November 11, 2025
Value of Additional Systematic Cores During Magnetic Resonance Imaging-guided Targeted Biopsy in Prostate Cancer Screening for Young Men: Results from the PROBASE TrialRouvier Al-Monajjed, Matthias Boschheidgen, Jale Lakes, et al.
Acta Neuropathologica|March 23, 2011
Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytomaHuriye Cin, Claus Meyer, Ricarda Herr, et al.
Blood Advances|September 30, 2024
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurinFrank G Rücker, Lars Bullinger, Sibylle Cocciardi, et al.
Nature Communications|September 22, 2020
The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolutionAlexej Ballhausen, Moritz Jakob Przybilla, Michael Jendrusch, et al.
Blood Advances|April 29, 2022
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplicationsHartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
Pageof 35